Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.
2.

Autotransplants in multiple myeloma: what have we learned?

Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1996 Aug 1;88(3):838-47.

3.

Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma.

Calasanz MJ, Cigudosa JC, Odero MD, García-Foncillas J, Marín J, Ardanaz MT, Rocha E, Gullón A.

Br J Haematol. 1997 Aug;98(2):418-25.

PMID:
9266942
4.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.

Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC).

Br J Haematol. 2007 Feb;136(4):615-23.

PMID:
17223915
5.

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.

Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B.

Br J Haematol. 2002 Jan;116(1):211-7.

PMID:
11841419
6.

Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.

Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T.

Blood. 1995 May 1;85(9):2490-7. Review.

7.

Hypodiploidy is a major prognostic factor in multiple myeloma.

Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C; Groupe Français de Cytogénétique Hématologique.

Blood. 2001 Oct 1;98(7):2229-38.

8.

Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells.

Gutiérrez NC, Hernández JM, García JL, Almeida J, Mateo G, González MI, Hernández J, Fernández-Calvo J, San Miguel JF.

Haematologica. 2000 Nov;85(11):1146-52.

9.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

10.

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfão A.

Blood. 1998 May 1;91(9):3366-71.

11.
12.

Long-term follow-up after high-dose therapy for high-risk multiple myeloma.

Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R.

Bone Marrow Transplant. 1998 Jun;21(11):1101-7.

13.

[Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].

Li Q, Lu Y, Wang YF, Liu XP, Qi JY, Zou DH, Zhao YZ, Qiu LG.

Zhonghua Yi Xue Za Zhi. 2009 Jul 28;89(28):1979-82. Chinese.

PMID:
19950573
14.

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.

Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R; Czech Myeloma Group.

Leuk Lymphoma. 2012 May;53(5):920-7. doi: 10.3109/10428194.2011.634042. Epub 2011 Dec 13.

PMID:
22023516
15.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G.

Blood. 2003 Sep 1;102(5):1588-94. Epub 2003 May 1.

16.

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B.

Br J Haematol. 2003 Jan;120(1):44-52.

PMID:
12492575
17.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A.

Blood. 1998 Oct 1;92(7):2322-33.

18.

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Kaufmann H, Krömer E, Nösslinger T, Weltermann A, Ackermann J, Reisner R, Bernhart M, Drach J.

Eur J Haematol. 2003 Sep;71(3):179-83.

PMID:
12930318
19.

Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.

Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M, Stipa E, Scimò MT, Masi M, Amadori S.

Cancer. 1996 Jun 15;77(12):2476-88.

20.

Prognostic value of cytogenetics in multiple myeloma.

Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R.

Br J Haematol. 1998 Apr;101(1):189-94.

PMID:
9576200

Supplemental Content

Support Center